EdgeMarket › What Casdin Capital, Llc reported owning
What Casdin Capital, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.3BPositions
40Quarter
2026-03-31Shown below
40largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | 250.6M | 19.0% | 2.6M | 209.46 | +479.3% |
| WGS GeneDx Holdings Corp. | 193.1M | 14.6% | 3.0M | 87.06 | -27.6% |
| RLAY Relay Therapeutics, Inc. | 143.5M | 10.9% | 14.4M | 19.44 | +471.8% |
| BLFS BIOLIFE SOLUTIONS INC | 113.7M | 8.6% | 6.0M | 37.10 | +48.6% |
| LAB STANDARD BIOTOOLS INC. | 81.6M | 6.2% | 88.8M | 0.67 | -45.6% |
| ILMN ILLUMINA, INC. | 65.3M | 4.9% | 530.0K | 219.40 | +117.7% |
| GPCR Structure Therapeutics Inc. | 56.6M | 4.3% | 1.2M | 49.09 | +164.4% |
| TXG 10x Genomics, Inc. | 48.3M | 3.7% | 2.3M | 65.12 | +387.4% |
| DNLI Denali Therapeutics Inc. | 35.3M | 2.7% | 1.8M | 24.92 | +71.7% |
| BEAM Beam Therapeutics Inc. | 32.2M | 2.4% | 1.4M | 29.76 | +85.3% |
| GH Guardant Health, Inc. | 29.1M | 2.2% | 315.0K | 170.69 | +191.8% |
| NGNE Neurogene Inc. | 28.6M | 2.2% | 1.4M | 38.63 | +97.0% |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | 24.8M | 1.9% | 75.0K | 236.22 | -48.5% |
| MAZE Maze Therapeutics, Inc. | 22.7M | 1.7% | 758.9K | 29.43 | +118.3% |
| SRRK Scholar Rock Holding Corp | 17.2M | 1.3% | 350.0K | 56.50 | +64.2% |
| AGMB Agomab Therapeutics NV | 16.3M | 1.2% | 1.6M | 13.25 | — |
| HIMS Hims & Hers Health, Inc. | 14.5M | 1.1% | 700.0K | 33.78 | -22.1% |
| TSHA Taysha Gene Therapies, Inc. | 14.5M | 1.1% | 3.2M | 6.09 | +112.2% |
| QGEN QIAGEN N.V. | 14.4M | 1.1% | 360.0K | 44.07 | -10.4% |
| TEM Tempus AI, Inc. | 13.3M | 1.0% | 294.1K | 72.69 | -0.8% |
| SEPN Septerna, Inc. | 13.3M | 1.0% | 553.3K | 40.00 | +260.7% |
| GRAL GRAIL, Inc. | 11.9M | 0.9% | 230.0K | 79.54 | +147.2% |
| PRME Prime Medicine, Inc. | 11.0M | 0.8% | 3.2M | 3.39 | +4.6% |
| PSNL Personalis, Inc. | 10.2M | 0.8% | 1.6M | 18.38 | +296.1% |
| DGX QUEST DIAGNOSTICS INC | 9.8M | 0.7% | 50.0K | 244.39 | +32.5% |
| VCYT VERACYTE, INC. | 8.9M | 0.7% | 276.3K | 42.31 | +43.5% |
| MLTX MoonLake Immunotherapeutics | 8.4M | 0.6% | 450.0K | 15.76 | -70.9% |
| NTLA Intellia Therapeutics, Inc. | 4.6M | 0.3% | 355.0K | 12.84 | +25.8% |
| IRON Disc Medicine, Inc. | 4.2M | 0.3% | 65.0K | 79.81 | +35.9% |
| MRNA Moderna, Inc. | 3.8M | 0.3% | 75.0K | 145.13 | +439.7% |
| ANL Adlai Nortye Ltd. | 3.7M | 0.3% | 538.5K | 13.70 | +720.4% |
| GLUE Monte Rosa Therapeutics, Inc. | 3.1M | 0.2% | 186.0K | 14.30 | +222.8% |
| ABSI Absci Corp | 2.9M | 0.2% | 973.3K | 9.55 | +271.6% |
| IPSC Century Therapeutics, Inc. | 2.8M | 0.2% | 1.2M | 2.07 | +279.8% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 2.5M | 0.2% | 282.3K | 9.08 | -5.7% |
| CTNM Contineum Therapeutics, Inc. | 1.9M | 0.1% | 148.3K | 17.19 | +93.8% |
| PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 955.4K | 0.1% | 723.8K | 1.35 | +6.3% |
| RXRX RECURSION PHARMACEUTICALS, INC. | 507.5K | 0.0% | 165.3K | 3.50 | -26.6% |
| TNYA Tenaya Therapeutics, Inc. | 250.6K | 0.0% | 362.0K | 0.70 | -43.8% |
| DNA Ginkgo Bioworks Holdings, Inc. | 223.7K | 0.0% | 36.5K | 7.40 | -36.2% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →